Genomics-first association of pharmacogenomic risk phenotypes with adverse drug reactions in a healthcare-based population

Pharmacogenomic (PGx) variation affects drug metabolism and adverse drug reaction (ADR) risk. While the Clinical Pharmacogenetics Implementation Consortium (CPIC) lists 573 actionable gene-drug pairs, large-scale evaluation of PGx-related ADRs remains limited. We performed a retrospective genomic-first analysis on genetic and electronic health record (EHR) data to assess PGx impact on ADR risk.